Correspondence 0001493152-25-027299 from Aspire Biopharma Holdings, Inc. (ASBP)
Aspire Biopharma Holdings, Inc.
Date: Dec. 11, 2025 · CIK: 0001847345 · Accession: 0001493152-25-027299
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291902
Letter
Aspire Biopharma Holdings, Inc.
Fashion Drive, Suite 232
Estero, Florida 33928
(908) 987-3002
December 11, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street NE
Washington, D.C. 20549
Re: Aspire Biopharma Holdings, Inc.
Registration Statement on Form S-1 File No. 333-291902
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the "Securities Act"), Aspire Biopharma Holdings, Inc. (the "Company") hereby requests that the Securities and Exchange Commission (the "Commission") take appropriate action to accelerate the effective date of the above-referenced registration statement on Form S-1 (the "Registration Statement") so as to become effective on December 12, 2025, at 5:00 PM Eastern Time, or as soon thereafter as practicable.
The Company hereby acknowledges that:
● Should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
● The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
● The Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If there is any change in the acceleration request set forth above, the Company will promptly notify you of the change, in which case the Company may be making an oral request of acceleration of the effectiveness of the Registration Statements in accordance with Rule 461 of Regulation C. Such request may be made by an executive officer of the Company or by any attorney from the Company's counsel, Sichenzia Ross Ference Carmel LLP.
Very truly yours,
Aspire Biopharma Holdings,
Inc.
Show Raw Text
CORRESP 1 filename1.htm Aspire Biopharma Holdings, Inc. 23150 Fashion Drive, Suite 232 Estero, Florida 33928 (908) 987-3002 December 11, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Re: Aspire Biopharma Holdings, Inc. Registration Statement on Form S-1 File No. 333-291902 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the "Securities Act"), Aspire Biopharma Holdings, Inc. (the "Company") hereby requests that the Securities and Exchange Commission (the "Commission") take appropriate action to accelerate the effective date of the above-referenced registration statement on Form S-1 (the "Registration Statement") so as to become effective on December 12, 2025, at 5:00 PM Eastern Time, or as soon thereafter as practicable. The Company hereby acknowledges that: ● Should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; ● The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and ● The Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. If there is any change in the acceleration request set forth above, the Company will promptly notify you of the change, in which case the Company may be making an oral request of acceleration of the effectiveness of the Registration Statements in accordance with Rule 461 of Regulation C. Such request may be made by an executive officer of the Company or by any attorney from the Company's counsel, Sichenzia Ross Ference Carmel LLP. Very truly yours, Aspire Biopharma Holdings, Inc. /s/ Kraig Higginson Kraig Higginson Chief Executive Officer